Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Emergency Department or Urgent Care Encounters and Hospitalizations Among Immunocompetent Adults — VISION Network, Nine States, September–November 2022
暂无分享,去创建一个
S. E. Reese | C. Mcevoy | R. Link-Gelles | P. Embí | K. Natarajan | S. Grannis | Zachary A Weber | B. Fireman | A. Naleway | M. Gaglani | Toan C Ong | J. Hansen | N. Klein | M. Tenforde | Stephanie A. Irving | M. DeSilva | N. Lewis | G. Vazquez-Benitez | Eric P. Griggs | A. Kharbanda | M. Dunne | K. Dascomb | Caitlin Ray | Julius Timbol | Jungmi Han | Kristin Goddard | Zhuang Yan | Monica Dickerson | Deepika Konatham | S. Rao | P. Patel | N. Grisel | Duck-Hye Yang | Julie Arndorfer | Kristin E. Schrader | M. Najdowski | Elizabeth A. K. Rowley | Sarah W. Ball | Ousseny Zerbo | Kempapura Murthy | Eddie Stenehjem
[1] M. Exline,et al. Early Estimates of Bivalent mRNA Vaccine Effectiveness in Preventing COVID-19–Associated Hospitalization Among Immunocompetent Adults Aged ≥65 Years — IVY Network, 18 States, September 8–November 30, 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[2] R. Link-Gelles,et al. Effectiveness of Bivalent mRNA Vaccines in Preventing Symptomatic SARS-CoV-2 Infection — Increasing Community Access to Testing Program, United States, September–November 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[3] R. Link-Gelles,et al. Interim Recommendations from the Advisory Committee on Immunization Practices for the Use of Bivalent Booster Doses of COVID-19 Vaccines — United States, October 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[4] William F. Fadel,et al. Effectiveness of COVID-19 mRNA Vaccines Against COVID-19–Associated Hospitalizations Among Immunocompromised Adults During SARS-CoV-2 Omicron Predominance — VISION Network, 10 States, December 2021—August 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[5] William F. Fadel,et al. Association between COVID-19 mRNA vaccination and COVID-19 illness and severity during Omicron BA.4 and BA.5 sublineage periods , 2022, medRxiv.
[6] D. Montefiori,et al. A Bivalent Omicron-Containing Booster Vaccine against Covid-19 , 2022, The New England journal of medicine.
[7] R. Iachan,et al. Seroprevalence of Infection-Induced SARS-CoV-2 Antibodies — United States, September 2021–February 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[8] William F. Fadel,et al. Effectiveness of a Third Dose of mRNA Vaccines Against COVID-19–Associated Emergency Department and Urgent Care Encounters and Hospitalizations Among Adults During Periods of Delta and Omicron Variant Predominance — VISION Network, 10 States, August 2021–January 2022 , 2022, MMWR. Morbidity and mortality weekly report.
[9] R. Myers,et al. Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant , 2021, The New England journal of medicine.
[10] Вестник КемГУ. Network , 2018, Definitions.